ProMetic Life Sciences (PFSCF) Stock Price, News & Analysis

Company Overview

ProMetic Life Sciences Inc. is a Canadian-based biotechnology company specializing in the discovery, development and commercialization of small-molecule drugs and biologics for the treatment of serious diseases. Headquartered in Laval, Québec, ProMetic leverages proprietary purification technologies—most notably its hydrophobic interaction chromatography platform—to advance both in-house therapeutic candidates and contract development projects for pharmaceutical and biotech clients around the world.

The company’s R&D pipeline focuses on fibrotic and metabolic disorders. Its lead compound, PBI-4050, is an orally administered small molecule being evaluated for indications such as idiopathic pulmonary fibrosis and systemic sclerosis. In addition, ProMetic is developing PBI-4547 for non-alcoholic steatohepatitis (NASH) and other metabolic diseases. These programs are supported by preclinical and clinical development teams operating in North America and Europe.

Beyond its internal pipeline, ProMetic offers contract development and manufacturing (CDMO) services, providing process development, scale-up and cGMP manufacturing support for plasma-derived and recombinant proteins. The company’s bioprocessing facilities in Québec and subsidiary operations in France serve a diverse roster of global clients, delivering customized purification solutions that address critical bottlenecks in downstream manufacturing.

Under the leadership of CEO Eric Althoff and a senior management team with decades of combined experience in pharmaceutical development, ProMetic Life Sciences continues to strengthen its platform capabilities while advancing late-stage programs toward regulatory milestones. The company’s integrated model aims to generate proprietary value through its pipeline while sustaining growth via service revenues from its CDMO business.

Key Stats

• Today's Range: $5.47 to $5.47
• 50-Day Range: $5.47 to $5.47
• 52-Week Range: $5.47 to $352.00
• Volume: N/A
• Average Volume: 279 shs
• Market Capitalization: $127.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PFSCF Stock Analysis - Frequently Asked Questions

How have PFSCF shares performed this year?

ProMetic Life Sciences' stock was trading at $5.4670 at the beginning of 2025. Since then, PFSCF shares have increased by 0.0% and is now trading at $5.4670.

How do I buy shares of ProMetic Life Sciences?

Shares of PFSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PFSCF
• Previous Symbol: NASDAQ:PFSCF
• CIK: N/A
• Web: www.prometic.com
• Phone: 1-450-781-0115
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$150.73 million
• Net Margins: -894.02%
• Pretax Margin: N/A
• Return on Equity: -3,350.55%
• Return on Assets: -67.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.95
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $36.55 million
• Price / Sales: 3.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($67.63) per share
• Price / Book: -0.08

Miscellaneous

• Outstanding Shares: 23,313,000
• Free Float: N/A
• Market Cap: $127.45 million
• Optionable: Not Optionable
• Beta: 2.46